Skip to main content
. 2024 Mar 8;5(3):101448. doi: 10.1016/j.xcrm.2024.101448

Figure 5.

Figure 5

The formation of TLS during the progression of early-stage LUAD

(A–D) Multiplex immunostaining analysis of TLSs for the following markers: CD20, CD4, CD8, CXCL13, and DAPI. Scale bars, 1 mm, 800 μm, 400 μm, and 50 μm.

(E–G) Multiplex immunostaining analysis of TLSs for the following markers: CD20, CD4, CD8, CD21, PNAd, and DAPI. The yellow, green, and red arrows refer to B cells, high endothelial venules, and follicular DCs. Scale bars, 50 μm.

(H–J) Quantification of CD20+ B cells, density of TLSs, and ratio of tumor area occupied by TLSs in nLung and patients with AIS, MIA, and IAC. nLung (n = 6), AIS (n = 6), MIA (n = 7), and IAC (n = 9). ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, two-sided Mann-Whitney U test. Bars and error bars represent mean +/- standard error.

(K) Quantification of different stages of TLSs in patients with AIS, MIA, and IAC. AIS (n = 6), MIA (n = 7), and IAC (n = 9). ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, two-sided Mann-Whitney U test.